ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case)
https://doi.org/10.21292/2078-5658-2016-13-3-63-70
Abstract
The article describes the follow-up over the development of atypical hemolytic-uremic syndrome in the female patient suffering menometrorrhagia which manifested with concurrent metrorrhagia and was accompanied with acute renal failure.
About the Authors
A. V. Pyregov
Research Center for Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Doctor of Medical Sciences, Head of Anesthesiology and Intensive Care Department
Russian Federation
Doctor of Medical Sciences, Head of Anesthesiology and Intensive Care Department
T. A. Fedorova
Research Center for Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Doctor of Medical Sciences, Head of Transfusiology and Extracorporal Hemocorrection Department
Russian Federation
Doctor of Medical Sciences, Head of Transfusiology and Extracorporal Hemocorrection Department
A. Yu. Korolev
Research Center for Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Doctor of Anesthesiology and Intensive Care Department
Russian Federation
Doctor of Anesthesiology and Intensive Care Department
K. I. Grischuk
Research Center for Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Doctor of Anesthesiology and Intensive Care Department
Russian Federation
Doctor of Anesthesiology and Intensive Care Department
References
1. Clinical recommendations for diagnostics and treatment of atypical hemolytic-uremic syndrome. Nefrologiya i dializ. 2015, vol. 17, no. 3, http://www.nephro. ru/content/files/242–264.pdf
2. Ariceta G., Besbas N., Johnson S. et al. European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diar-rhea-negative hemolytic uremic syndrome. Pediatr. Nephrol., 2009, vol. 24, pp. 687-696.
3. Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int., 2006, vol. 70, pp. 423-431.
4. Campistol J.M., Arias M., Ariceta G. et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia, 2013, vol. 33, pp. 27-45.
5. Caprioli J., Noris M., Brioschi S. et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood, 2006, vol. 108, pp. 1267-1279.
6. Cataland S.R., Wu H.M. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur. J. Intern. Med., 2013, vol. 24, pp. 486-491.
7. Cataland S.R., Yang S., Wu H.M. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br. J. Haematol., 2012, vol. 157, pp. 501-503.
8. Cataland S.R. Complement biomarkers and diagnosis of aHUS. Blood 2014, vol. 123, no. 24, URL: ncbi.nlm.nih.gov
9. Chan M.R., Thomas C.P., Torrealba J.R. et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am. J. Kidney Dis., 2009, vol. 53, pp. 321-326.
10. Constantinescu A.R., Bitzan M., Weiss L.S. et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am. J. Kidney Dis., 2004, vol. 43, pp. 976-982.
11. Coppo P., Schwarzinger M., Buffet M. et al. French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One, 2010, vol. 5, pp. e10208.
12. Donne R.L., Abbs I. Reccurence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am. J. Kidney Dis., 2002, URL: ncbi.nlm.nih.gov_ajkd.org
13. Dragon-Durey M.A., Sethi S.K., Bagga A. et al. Clinical features of anti-factor H autoantibody_associated hemolytic uremic syndrome. J. Am. Soc. Nephrol., 2010, vol. 21, pp. 2180-2187.
14. Fremeaux-Bacchi V., Fakhouri F., Garnier A. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol., 2013, vol. 8, pp. 554-562.
15. Gasser C., Gautier E., Steck A. et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med. Wochenschr., 1955, vol. 85, pp. 905-909.
16. Greenbaum L.A., Fila M., Tsimaratos M. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (pts). Presented at American Society of Nephrology (ASN) Kidney Week 2013, Atlanta, Ga., November 9, 2013.
17. Hofer J., Rosales A., Fischer C. et al. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front. Pediatr., 2014, vol. 2, pp. 97.
18. Kavanagh D., Goodship T.H. Atypical hemolytic uremic syndrome, genetic basis and clinical manifesatations. Hematology Am. Soc. Hemat. Educ. Program. 2011, pp. 15-17. URL: ncbi.nlm.nih.gov
19. Keating G.M. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs, 2013, vol. 73, pp. 2053-2066.
20. Keir L., Coward R.J. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr. Nephrol., 2011, vol. 26, pp. 523-533.
21. Kremer Hovinga J.A., Vesely S.K., Terrell D.R. et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, vol. 115, pp. 1500-1511.
22. Legendre C.M., Licht C., Muus P. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med., 2013, vol. 368, pp. 2169-2181.
23. Loirat C., Freaux-Bacchi V. Atipical hemolytic-uremic syndrome. Orhanet. J. Rare Dis., 2011, vol. 8, pp. 6-60.
24. Noris M., Caprioli J., Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol., 2010, vol. 5, pp. 1844-1859.
25. Noris M., Galbusera M., Gastoldi S. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, vol. 124, pp. 1715-1726.
26. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med., 2009, vol. 361, pp. 1676-1687.
27. Noris M., Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat. Rev. Nephrol., 2014, vol. 10, pp. 174-180.
28. Pourrat O., Coudroy F.P. Differentiation between severe HELLP syndrome and trombotic microangiopathy, trombotic thrombocytopenic purpura and other imitators. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2015, vol. 189, pp. 68-72.
29. Rafiq A. Atypical hemolytic-uremic syndrome. Am. J. Case Rep., 2015, vol. 16, pp. 109-114.
30. Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr. Nephrol., 2014, vol. 29, pp. 329-332.
31. Sanches-Corral P., Melgosa M. Advanced in understanding aetiogy of atupical hemolytic uraemic syndrome. Br. J. Haemotol., 2010, vol. 150, pp. 529-542.
32. Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br. J. Haematol., 2014, vol. 164, pp. 759-766.
33. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A. et al. French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol., 2007, vol. 18, pp. 2392-2400.
34. Shrivastava M. Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange. Transfus. Apheresis Sci., 2011, vol. 44, pp. 257-262.
35. Thompson R.A., Winterborn M.H. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin. Exp. Immunol., 1981, vol. 46, pp. 110-119.
36. Warwicker P., Goodship T.H., Donne R.L. et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int., 1998, vol. 53, pp. 836-844.
37. Wong E.K., Goodship T.H., Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol. Immunol., 2013, vol. 56, pp. 199-212.
38. Zuber J., Fakhouri F., Roumenina L.T. et al. French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol., 2012, vol. 8, pp. 643-657.
39. Zuber J., Le Quintrec M., Morris H. et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev. (Orlando), 2013, vol. 27, pp. 117-125.
Review
For citations:
Pyregov A.V., Fedorova T.A., Korolev A.Yu., Grischuk K.I. ATYPICAL HEMOLYTIC-UREMIC SYNDROME IN THE FEMALE PATIENT WITH CONCURRENT MENOMETRORRHAGIA (clinical case). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2016;13(3):63-70. (In Russ.) https://doi.org/10.21292/2078-5658-2016-13-3-63-70
Email this article 